GlassScriptPhysician profile
Mohammad Qazi
NPI 1588956726
$1,438.68
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.88 · 2020: $701 · 2021: $703 · 2023: $18.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.87 | 2019-2021 | |
| Pfizer INC. | $237.10 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $205.31 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $192.68 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $129.16 | 2020-2021 | |
| Amgen INC. | $110.43 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $78.59 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $54.24 | 2020 | |
| Akcea Therapeutics, INC. | $46.24 | 2020 | |
| Lundbeck LLC | $34.33 | 2020 | |
| Medtronic, INC. | $31.13 | 2021 | |
| Merck Sharp & Dohme LLC | $25.00 | 2021 | |
| Lantheus Medical Imaging, INC. | $18.02 | 2023 | Definity |
| Biotronik INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.